Gene therapy joins fight against tough breast cancer
NCT ID NCT04095689
Summary
This study tested a combination of three treatments for an aggressive type of breast cancer that had stopped responding to standard chemotherapy. It combined chemotherapy (docetaxel), an immunotherapy drug (pembrolizumab), and a gene therapy designed to boost the immune system. The goal was to see if this three-part approach could shrink tumors more effectively before surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Houston Methodist Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.